Best Life Sciences Companies in Canton of Zug, Switzerland
The 48 best Life Sciences companies in Canton of Zug, Switzerland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Sanoptis.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Canton of Zug
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Sanoptis Network of eye clinics and practices offering ophthalmological services. | $270M | 16 mo ago | Acquired | Volker Wendel CEO | 2018 | WordPressMySQLPHP+20 | — | 1 job opening |
| 2 | Arvelle Therapeutics Developer of small molecule therapies for the treatment of CNS disorders | $223M | 74 mo ago | Acquired | — | 2019 | — | — | — |
| 3 | Cardiorentis Developer of natriuretic peptides for the treatment of cardiovascular diseases | $119M | 127 mo ago | Deadpooled | Johannes Holzmeister CEO | 2010 | — | 30 patents Patents concentrated in health & consumer products | — |
| 4 | 4D Lifetec Developer of a diagnostic test for genotoxicity to diagnose multiple cancers | $37M | 33 mo ago | Series C | — | 2014 | — | 28 patents Cancer screening via single‑cell electrophoresis detecting DNA‑damage biomarkers | — |
| 5 | AmVac Vaccine developer for the treatment of infections and urogenital conditions | $15M | 157 mo ago | Deadpooled | Ali Pashazadeh CEO | 2005 | — | 29 patents Recombinant negative‑strand RNA viral vectors for heterologous protein expression and RSV semi‑live vaccines | — |
| 6 | Sellas Life Sciences Developer of therapeutics for the treatment of cancer | $14M | 72 mo ago | Public | — | 2006 | WordPressPleskMySQL+19 | — | — |
| 7 | Berlin Heals Developer of a microcurrent device for heart failure treatment. | $12M | 6 mo ago | Series B | Peter Goettel Co-Founder & Co-CEO | 2010 | GSAPApache HTTP ServerCloudflare+5 | 20 patents Patents concentrated in health & consumer products | — |
| 8 | Demiurge Technologies Developer of neural network models and neuromorphic chips | $10M | 127 mo ago | Series A | — | 2015 | — | — | — |
| 9 | Mybacs Manufacturer of probiotic products for digestion | $6M | 33 mo ago | Series A | Adrian Weingart Co-Founder | 2018 | Cart FunctionalityShopifySentry+46 | — | 2 job openings · 1 launch |
| 10 | Deep Breath Intelligence Developer of AI and mass spectrometry-based platform for personalized medicine | $3M | 48 mo ago | Seed | Guillermo Vidal-De-Miguel Co-Founder | 2018 | — | 3 patents Advanced high‑pressure gas storage systems for industrial and energy applications | — |
| 11 | AVA Biochem Developer of bio-based platform chemicals derived from renewable feedstocks | $2M | 63 mo ago | Funding Raised | — | 2014 | — | 14 patents Patents concentrated in chemistry & materials | — |
| 12 | Laevoroc Oncology Developer of therapeutics for cancer | $1M | 63 mo ago | Seed | Thomas Mehrling Founder-CEO at Laevoroc | 2019 | — | — | — |
Top 12 Life Sciences companies in Canton of Zug
#1
Series B · Zug, Canton of Zug · founded 2010 · 19 employees$11.9Mraised▾
{}
- Feb 2026Series B$10M
- Sep 2025Series A$5M
- Feb 2025Series A$7.8M
- Jun 2023Series A$6.7M
#2
Acquired · Zug, Canton of Zug · founded 2018 · 500 employees$269.9Mraised▾
Network of eye clinics and practices offering ophthalmological services. It provides a platform for modern eye clinics and practices. The company facilitates collaborations, investments, and training for improved patient care. It fosters knowledge sharing among medical professionals. The company supports recruitment and development of medical staff. It advises clinics and practices on optimizing operations, personnel, finance, and marketing. The company invests in equipment and facilities to ensure treatment in a comfortable environment.
- Mar 2025PE$269.9M
#3
Series C · Zug, Canton of Zug · founded 2014 · 6 employees$36.8Mraised▾
Developer of a diagnostic test for genotoxicity to diagnose multiple cancers. The product is based on the company's technology platform called 4D Lifetest, based on the Single Cell Gel Electrophoresis Technology (SCGE). This automated molecular test system can be used for many other applications such as human and environmental biomonitoring, human infertility analysis, or the testing of genotoxicity of substances in accordance with the OECD guideline.
- Oct 2023Series C$25.9M
- Jul 2022Series B$1.9M
- Jun 2019Series B$9M
#4
Acquired · Zug, Canton of Zug · founded 2019 · 60 employees$222.7Mraised▾
Developer of small molecule therapies for the treatment of CNS disorders. The lead candidate Cenobamate is being developed for the treatment of partial-onset seizures in adult patients. The mechanism of action of the lead is the modulation of GABA-A receptors and inhibition of sodium current.
- May 2020Series A$42.7M
- Feb 2019Series A$180M
#5
Deadpooled · Zug, Canton of Zug · founded 2010 · 9 employees$118.5Mraised▾
Cardiorentis develops drug therapies for the treatment of acute heart failure and related cardiovascular diseases. The company is developing a peptide, ularitide, which is an intravenous infusion treatment for acute heart failure. Ularitide is the pharmaceutical version of urodilatin, which is an amino acid hormone of the natriuretic peptide family, secreted from the distal tubules of the kidney.
- Jan 2016Series B$60.3M
- Sep 2014Series A$58.3M
#6
Series A · Baar, Canton of Zug · founded 2018 · 27 employees$5.9Mraised▾
Mybacs manufactures and markets probiotic supplements for digestion. The products provided are for every day or trip. The products are a mixture of gut bacteria, vitamins, proteins, and minerals. The product can help in digestion, cardiac problem, and others.
- Oct 2023Series A$5.9M
- Jul 2020Seed—
- Aug 2019Seed—
#7
Public · Zug, Canton of Zug · founded 2006 · 17 employees$13.9Mraised▾
Developer of therapeutics for the treatment of cancer. The company is focused on the development of novel therapeutics for a broad range of cancer indications which include galinpepimut-S a cancer immunotherapeutic agent that targets the Wilms tumor 1 and SLS009, a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
- Jul 2020Post IPO$9.2M
- May 2018Post IPO$4.7M
#8
Deadpooled · Zug, Canton of Zug · founded 2005 · 11 employees$15.1Mraised▾
AmVac AG is a vaccine developer for the treatment and prevention of widespread infections and urogenital conditions. The portfolio comprises five vaccine candidates and three platform technologies: the Lactobacillus, Sendai and MALP platforms, in-licensed from a Hungarian partner and German institutes of the Helmholtz Association and Max Planck Society. The company's lead product has gained market approval in selected indications and is currently being developed for the treatment of a broad range of urogenital diseases. The company has received two EU Grants for the development of novel vaccines.
- Jun 2013Series B$12.3M
- Feb 2010Series A$2.8M
#9
Seed · Risch Rotkreuz, Canton of Zug · founded 2018 · 10 employees$2.9Mraised▾
Developer of AI and mass spectrometry-based platform for personalized medicine. The company is developing a DBI-EPIbreath®, which is a test for drug monitoring in epilepsy. This platform is used for personalized medicine for epilepsy, monitoring COPD, and metabolism.
- Jul 2022Seed$2.9M
#10
Series A · Zug, Canton of Zug · founded 2015 · 4 employees$9.5Mraised▾
Demiurge Technologies is an artificial intelligence company that develops neural network models and neuromorphic chips. Claims to offers consciousness-inspired neuromorphic chips. It also provides artificial intelligence design service for neuromorphic chips and biomorphic robots based on a novel spiking neural network model.
- Dec 2015Series A$7.7M
- Dec 2015Angel$1.8M
#11
Funding Raised · Zug, Canton of Zug · founded 2014$1.7Mraised▾
Developer of bio-based platform chemicals derived from renewable feedstocks. The company’s hydrothermal processing technology converts industrial sugars into a versatile bio-based molecule. This molecule can replace petroleum-sourced chemicals in mass-market applications. Target applications include biopolymers, resins, and adhesives, offering sustainable alternatives.
- May 2021Grant (prize money)$527.8K
- Jan 2019Grant (prize money)$342K
- Jan 2018Grant (prize money)$60.3K
- Jan 2018Grant (prize money)$472.9K
#12
Seed · Hunenberg, Canton of Zug · founded 2019 · 4 employees$1.1Mraised▾
Developer of therapeutics for cancer. The drug candidates include LR 06 an oral gemcitabine prodrug for pancreatic, ovarian, and breast cancers, LR09 guides the immune system to eradicate relapsed leukemia after allogeneic stem cell transplantation, and LR02 is a central nervous system ATR inhibitor for treating brain cancer.
- May 2021Seed$1.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Switzerland
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 469 Switzerland-affiliated papers.
- ETH Zurich52
- University of Zurich40
- University of Lausanne34
- Agroscope30
- University of Basel30
- Gene2→9
- Chromatin1→8
- Antibody3→7
- Epitope1→5
- Immune system1→4
- Population2→4
- Antimicrobial1→5
- Context (archaeology)1→4
- Agriculture2→4
Where biotechnology is researched across Switzerland
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.